Afacifenacin

Drug Profile

Afacifenacin

Alternative Names: Afacifenacin fumarate; NS-986; SMP-986

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Nippon Shinyaku; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Piperidines; Quinazolinones; Small molecules; Urologics
  • Mechanism of Action Muscarinic receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nocturia
  • No development reported Overactive bladder

Most Recent Events

  • 29 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Japan, European Union (PO)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 13 May 2014 Phase-II clinical trials in Nocturia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top